Infographic: What You Need to Know About Biosimilar Filgrastim and Neutropenia

How much money can biosimilar filgrastim save, and how can health systems encourage uptake? This infographic outlines 7 key concepts.

Related Content:

Oncology

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

Denosumab, Golimumab Biosimilars Clear Major Regulatory Milestones in Europe, as US Hurdles Remain

Medicare Modeling Shows Major Savings With Biosimilar Bevacizumab Use